Do different methods of modeling statin treatment effectiveness influence the optimal decision?

Medical Decision Making

Volumn 32, Issue 3, 2012, Pages 507-516

  Van Kempen, Bob J H ^a   Ferket, Bart S ^a   Hofman, Albert ^a   Spronk, Sandra ^a   Steyerberg, Ewout ^a   Hunink, M G Myriam ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cardiovascular disease; cost effectiveness analysis; model uncertainty; statins; structural uncertainty

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG EFFECT; ECONOMICS; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; PROBABILITY; PROPORTIONAL HAZARDS MODEL; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL MODEL; STROKE; TIME; UNCERTAINTY;

AGED; CHOLESTEROL, LDL; CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MODELS, STATISTICAL; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PROBABILITY; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; STROKE; TIME FACTORS; UNCERTAINTY;

EID: 84861797539     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X12439754     Document Type: Article

References (33)

1. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010 ; 152: 69-77
2. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009 ; 150: 243-54
3. Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010 ; 362: 590-9
4. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med. 1998 ; 158: 655-62
5. Jacobs-van der Bruggen MA, Engelfriet PM, Hoogenveen RT, et al. Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands. Eur J Cardiovasc Prev Rehabil. 2008 ; 15: 521-5
6. Kongnakorn T, Ward A, Roberts CS, O'Brien JA, Proskorovsky I, Caro JJ. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health. 2009 ; 12: 880-7
7. Kottke TE, Faith DA, Jordan CO, Pronk NP, Thomas RJ, Capewell S. The comparative effectiveness of heart disease prevention and treatment strategies. Am J Prev Med. 2009 ; 36: 82-8
8. Martikainen JA, Soini E, Paulsson T. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden. Curr Med Res Opin. 2010 ; 26: 389-96
9. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006 ; 144: 326-36
10. Roze S, Liens D, Palmer A, Berger W, Tucker D, Renaudin C. A health economic model to determine the long-term costs and clinical outcomes of raising low HDL-cholesterol in the prevention of coronary heart disease. Curr Med Res Opin. 2006 ; 22: 2549-56
11. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM. Population strategies to decrease sodium intake and the burden of cardiovascular disease: a cost-effectiveness analysis. Ann Intern Med. 2010 ; 152: 481-7
12. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-39
13. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health. 1987 ; 77: 1417-26
14. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol. 1998 ; 82: 1357-63
15. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991 ; 265: 1145-51
16. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA. 1995 ; 273: 1032-8
17. Martens LL, Rutten FF, Erkelens DW, Ascoop CA. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in the Netherlands. Am J Cardiol. 1990 ; 65: 27F - 32F
18. Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovasculardisease risk. Lancet. 2003 ; 361: 717-25
19. Greving J, Visseren F, de Wit G, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ. 2011 ; 342: d1672
20. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart. 1999 ; 81: 380-6
21. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006 ; 368: 679-86
22. Nijhuis RL, Stijnen T, Peeters A, Witteman JC, Hofman A, Hunink MG. Apparent and internal validity of a Monte Carlo-Markov model for cardiovascular disease in a cohort follow-up study. Med Decis Making. 2006 ; 26: 134-44
23. Hofman A., et al. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol. 2011 ; 26 (8). 657-86
24. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009 ; 338: b2376
25. Bots ML, Elwood PC, Nikitin Y, et al. Total and HDL cholesterol and risk of stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002 ; 1: i19-24
26. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-78
27. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002 ; 106: 3143-421
28. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006 ; 97: 52C - 60C
29. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 2007 ; 16: 307-17
30. Groot Koerkamp B, Weinstein MC, Stijnen T, Heijenbrok-Kal MH, Hunink MG. Uncertainty and patient heterogeneity in medical decision models. Med Decis Making. 2010 ; 30: 194-205
31. Yeung AC, Tsao P. Statin therapy: beyond cholesterol lowering and antiinflammatory effects. Circulation. 2002 ; 105: 2937-8
32. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006 ; 109: 7-15
33. Red Book 2009: Pharmacy's Fundamental Reference (Red Book Drug Topics). 2009: Pharmacy's Fundamental Reference (Red Book Drug Topics). 113th ed.New York: Thomson Reuters; 2009. New York: Thomson Reuters ; 2009 :